Horizon Technology Finance Corporation (NASDAQ: HRZN) ("Horizon") (the "Company"), an affiliate of Monroe Capital, today announced it has provided a $50 million venture loan facility to Pelthos ...

Discover why psoriasis treatments may lose effectiveness and explore alternatives. Learn about the potential of biologics, ...

The cost of Rogaine® typically ranges from about $30 to $45, depending on the retailer and product type. Many stores also ...

It was found that adding NB-UVB light therapy to ruxolitinib (Opzelura) 1.5% cream helped many vitiligo patients who did not respond early to treatment achieve faster and more noticeable skin ...

Eric Donnenfeld’s corneal health case presentations and panel discussion at OSN New York are always popular with meeting ...

Not only can this cause dryness and discomfort, the urethra sometimes doesn’t seal properly, and bacteria can get into the ...

Continued strong growth of ZORYVE® (roflumilast) in 2026 with full-year net product sales guidance of $455–$470 millionAdvancement of ZORYVE ...

Trachoma is the leading cause of infectious blindness in the world, with Ethiopia the most impacted country in Africa. In a ...

Royalty Pharma to provide up to $500 million, including $75 million for Phase 2b funding and a Royalty Pharma option for an additional $425 ...

Mild hidradenitis suppurativa is often treated with cycles of steroids and antibiotics that have adverse effects. Can an anti ...

Delgocitinib cream and dupilumab have similar efficacy at 16 weeks of treatment in patients with moderate to severe atopic hand eczema.

Tralokinumab plus optional use of TCS or TCI in adults with moderate to severe AD was associated with stable disease control for up to 4 years.